Revlimid (lenalidomide) [product monograph]. HC.

Regulatory approval published by the Health Canada.

Citation

Bristol-Myers Squibb Canada. Revlimid (lenalidomide) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00074535.PDF. Published February 2024. Accessed June 2025.

View API

Regulatory approvals

Approved indications from this document for cancer drugs containing at least one biomarker.

Indication Statements
REVLIMID (lenalidomide) is indicated for the treatment of patients with transfusion-dependent anemia due to Low- or Intermediate-1-risk myelodysplastic syndromes associated with a deletion 5q cytogenetic abnormality with or without additional cytogenetic abnormalities. Approval for this indication is based on red blood cell transfusion independence response rates. Overall survival benefit has not been demonstrated. 1

Therapeutic response

Precision oncology relationships for therapeutic response derived from this document.

Type Biomarker(s) Cancer type Therapy(ies)
Sensitivity (+) 5q deletion Myelodysplastic Syndromes Lenalidomide